- Research Services
- Antibody Discovery
- Antibody and Protein Engineering
- Cell Line Development
- Development & Manufacturing
- Investor Relations
- Contact Us
EpiScreen™ – DC:T cell assay
The EpiScreen™ DC:T cell assay is used to assess the potential immunogenicity of antibodies and proteins that directly modulate T cell activation and to assess the ‘adjuvant effect’ of different product formulations on immunogenicity.
Assays are performed using dendritic cells (DC) derived from peripheral blood mononuclear cells (PBMCs), typically from 50 individual donors, with a distribution of HLA-DR allotypes (coverage and frequency) representing the human population of interest.
The DCs are differentiated in vitro to a immature DC phenotype. These cells are then loaded with the test protein or formulation before inducing further differentiation to a mature DC phenotype. Once matured, the cells are incubated with autologous CD4+ T cells before measuring T cell proliferation and IL-2 secretion, both markers of T cell activation, using 3H-thymidine incorporation and ELISpot, respectively.
Prescreen tests using a small numbers of donors can be performed to evaluate if there is direct modulation of T cell activation prior to choosing a time course or DC:T cell assay.
Working with Abzena
Abzena’s services are tailored for each project to ensure that the objectives are met or exceeded. Experienced project teams are assigned to each study focusing on progressing projects through to results in the minimum amount of time. Our clients widely regard us as professional and attentive partners who deliver quality results. D:C T cell assays are usually completed in 10-12 weeks depending on the number of proteins run in parallel.
To get more information, a quote or to schedule a teleconference please contact us.